Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Bekaii-Saab Highlights Targeted Therapy Advances in CRC

June 2nd 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses the growing role of targeted therapy in CRC.

Metastatic Gastric Cancer: Recent Advances and Future Directions

June 2nd 2020

Perioperative Strategies in Metastatic Gastric Cancer

June 2nd 2020

Metastatic Gastric Cancer: Promising Later-Line Trials

June 2nd 2020

Metastatic Gastric Cancer: Promising Second-Line Trials

June 2nd 2020

Metastatic Gastric Cancer: Novel Agents Targeting FGF

June 2nd 2020

Gastric Cancer: Frontline Checkpoint Inhibitor Trials

June 2nd 2020

Metastatic Gastric Cancer: Promising Frontline Trials

June 2nd 2020

Emerging Biomarkers in Metastatic Gastric Cancer

June 2nd 2020

Later Lines of Therapy in Metastatic Gastric Cancer

June 2nd 2020

Chemotherapy + Ramucirumab as Second-Line Therapy in mGC

June 2nd 2020

Global Use of Second-Line Therapy in mGC

June 2nd 2020

Metastatic Gastric Cancer: Identifying Disease Progression

June 2nd 2020

Switch Maintenance in Gastric Cancer: Results of JAVELIN Gastric 100

June 2nd 2020

Gastric Cancer: Global Perspectives on Maintenance Therapy

June 2nd 2020

Is Frontline IO Therapy Appropriate in Gastric Cancer?

June 2nd 2020

Metastatic Gastric Cancer: Factors in Selecting Frontline Therapy

June 2nd 2020

Global Use of Frontline Therapy in Metastatic Gastric Cancer

June 2nd 2020

Olaparib Approaches EU Approval for Frontline Maintenance in Pancreatic Cancer

June 1st 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended olaparib for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma.

Trastuzumab Deruxtecan Shows Promising Clinical Activity in CRC and Gastric/GEJ Tumors

May 31st 2020

Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated promising clinical activity in patients with HER2-positive metastatic colorectal cancer, as well as in those with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.